The FDA has suggested changes to trials for diabetes drugs, which may delay approval of a once-weekly form of exenatide, a diabetes treatment Amylin Pharmaceuticals is developing with Eli Lilly and Co. and Alkermes. Amylin has already released promising Phase III trial data for the drug's long-acting version but said it does not expect to seek FDA approval before mid-2009.

Full Story:

Related Summaries